| 注射用紫杉醇(清蛋白结合型)抗肿瘤作用* |
| |
| 引用本文： | 王彩霞,高玉清,李艳玲,毕宇鑫,魏娜,赵倩,李春雷.注射用紫杉醇(清蛋白结合型)抗肿瘤作用*[J].骨科,2015,34(4):459-463. |
| |
| 作者姓名： | 王彩霞 高玉清 李艳玲 毕宇鑫 魏娜 赵倩 李春雷 |
| |
| 作者单位： | 1.石药集团中奇制药技术(石家庄)有限公司,石家庄050035;2.新型药物制剂与辅料国家重点实验室,石家庄050035,1.石药集团中奇制药技术(石家庄)有限公司,石家庄050035;2.新型药物制剂与辅料国家重点实验室,石家庄050035,1.石药集团中奇制药技术(石家庄)有限公司,石家庄050035;2.新型药物制剂与辅料国家重点实验室,石家庄050035,1.石药集团中奇制药技术(石家庄)有限公司,石家庄050035;2.新型药物制剂与辅料国家重点实验室,石家庄050035,1.石药集团中奇制药技术(石家庄)有限公司,石家庄050035;2.新型药物制剂与辅料国家重点实验室,石家庄050035,1.石药集团中奇制药技术(石家庄)有限公司,石家庄050035;2.新型药物制剂与辅料国家重点实验室,石家庄050035,1.石药集团中奇制药技术(石家庄)有限公司,石家庄050035;2.新型药物制剂与辅料国家重点实验室,石家庄050035 |
| |
| 摘 要： | 目的比较自研注射用紫杉醇(清蛋白结合型,PAB)与原研注射用紫杉醇(清蛋白结合型,Abraxane)的体内抗肿瘤作用。方法建立小鼠H22、Lewis和RM-1肿瘤模型,荷瘤小鼠分别静脉注射13.4,20.0,30.0,45.0 mg·kg-1剂量的PAB和20.0和(或)30.0 mg·kg-1剂量的Abraxane,比较给药后PAB组与Abraxane组的抗肿瘤作用。结果PAB 13.4,20.0,30.0,45.0 mg·kg-1剂量组均能显著抑制H22肿瘤生长,PAB 20.0 mg·kg-1剂量组与等剂量的Abraxane组比较对H22肿瘤地抑制作用差异无统计学意义。PAB 20.0,30.0,45.0 mg·kg-1剂量组可剂量依赖性地抑制Lewis和RM-1肿瘤生长,PAB和Abraxane对C57雌性荷瘤小鼠的最大无毒剂量均为20.0 mg·kg-1。PAB各剂量组与等剂量的Abraxane组比较,对RM-1和Lewis肿瘤生长的抑制作用和对荷瘤小鼠的毒性均差异无统计学意义。结论相同给药剂量下,PAB的体内抗肿瘤作用和毒性与原研品Abraxane相同。
|
| 关 键 词： | 紫杉醇 清蛋白 抗肿瘤 |
Antitumor Effect of Paclitaxel for Injection (Albumin Bound) |
| |
| WANG Caixi,GAO Yuqing,LI Yanling,BI Yuxing,WEI N,ZHAO Qian,LI Chunlei,WANG Caixi,GAO Yuqing,LI Yanling,BI Yuxing,WEI N,ZHAO Qian,LI Chunlei,WANG Caixi,GAO Yuqing,LI Yanling,BI Yuxing,WEI N,ZHAO Qian,LI Chunlei,WANG Caixi,GAO Yuqing,LI Yanling,BI Yuxing,WEI N,ZHAO Qian,LI Chunlei,WANG Caixi,GAO Yuqing,LI Yanling,BI Yuxing,WEI N,ZHAO Qian,LI Chunlei,WANG Caixi,GAO Yuqing,LI Yanling,BI Yuxing,WEI N,ZHAO Qian,LI Chunlei,and WANG Caixi,GAO Yuqing,LI Yanling,BI Yuxing,WEI N,ZHAO Qian,LI Chunlei.Antitumor Effect of Paclitaxel for Injection (Albumin Bound)[J].Orthopaedics,2015,34(4):459-463. |
| |
| Authors: | WANG Caixi GAO Yuqing LI Yanling BI Yuxing WEI N ZHAO Qian LI Chunlei WANG Caixi GAO Yuqing LI Yanling BI Yuxing WEI N ZHAO Qian LI Chunlei WANG Caixi GAO Yuqing LI Yanling BI Yuxing WEI N ZHAO Qian LI Chunlei WANG Caixi GAO Yuqing LI Yanling BI Yuxing WEI N ZHAO Qian LI Chunlei WANG Caixi GAO Yuqing LI Yanling BI Yuxing WEI N ZHAO Qian LI Chunlei WANG Caixi GAO Yuqing LI Yanling BI Yuxing WEI N ZHAO Qian LI Chunlei and WANG Caixi GAO Yuqing LI Yanling BI Yuxing WEI N ZHAO Qian LI Chunlei |
| |
| Abstract: | ObjectiveTo compare the antitumor effect of self-developed albumin bound paclitaxel for injection (PAB) and commercial albumin-bound paclitaxel for injection (Abraxane).MethodsThe antineoplastic effects of PAB and Abraxane were evaluated in H22, Lewis and RM-1 allograft tumor mouse models after repeated intravenous injection (13.4, 20.0, 30.0 and 45.0 mg·kg-1 PAB and 20.0 and/or 30.0 mg·kg-1 Abraxane, respectively).ResultsPAB significantly inhibited H22 tumor growth at from the doses of 13.4, 20.0, 30.0, and 45.0 mg·kg-1 ,and the antitumor effect of PAB at 20.0 mg·kg-1 was not significantly different from Abraxane at 20.0 mg·kg-1.PAB dose-dependently inhibited Lewis and RM-1 tumor growth at the doses of 20.0, 30.0, and 45.0 mg·kg-1.The no observed adverse effect level of PAB and Abraxane was 20.0 mg·kg-1 in Lewis and RM-1 bearing C57 female mice.The antitumor effect and toxicity was not significantly different between PAB and Abraxane at equivalent doses.ConclusionAt the same dose level, the antitumor activity and toxicity of PAB was equivalent to those of Abraxane. |
| |
| Keywords: | Paclitaxel Albumin bound Antitumor effect |
|
| 点击此处可从《骨科》浏览原始摘要信息 |
|
点击此处可从《骨科》下载全文 |
|
